SCHEMBL5848015

SCHEMBL5848015

O=C(Nc1ccc2c(c1)CCC(C(=O)O)O2)C1CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.50
NFKB1 P19838 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 3/20 0.46
MAPK14 Q16539 2/20 0.46
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
MAPT P10636 3/20 0.44
GAA P10253 3/20 0.44
GFER P55789 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
HPGD P15428 2/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
RAB9A P51151 3/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5848023 1.00 NPC1 (0.50) NPC1NFKB1NFKB2RELAKDM4E
SCHEMBL5848018 1.00 NPC1 (0.50) NPC1NFKB1NFKB2RELAKDM4E
SCHEMBL5847426 0.85 CYP2D6 (0.52) NPC1NFKB1NFKB2RELAKDM4E
SCHEMBL5847418 0.85 CYP2D6 (0.52) NPC1NFKB1NFKB2RELAKDM4E
SCHEMBL5847422 0.85 CYP2D6 (0.52) NPC1NFKB1NFKB2RELAKDM4E
SCHEMBL5847599 0.78 CYP2D6 (0.53) NPC1NFKB1NFKB2RELASMN1; SMN2
SCHEMBL5847604 0.78 CYP2D6 (0.53) NPC1NFKB1NFKB2RELASMN1; SMN2
SCHEMBL5847594 0.78 CYP2D6 (0.53) NPC1NFKB1NFKB2RELASMN1; SMN2
SCHEMBL4672071 0.77 CYP4F2 (0.44) NFKB1NFKB2RELA
SCHEMBL5846797 0.77 CYP4F2 (0.44) NFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034051-B2 Fused bicyclic carboxamide derivatives and methods of their use ADOLOR CORPORATION (US) 2006-04-25 US disclosed
WO-2005023799-A1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2005-03-17 WO disclosed
US-20050054630-A1 Fused bicyclic carboxamide derivatives and methods of their use CUBIST PHARMACEUTICALS, INC. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054630-A1 Fused bicyclic carboxamide derivatives and methods of their use PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 NPC1 740/4885NFKB1 3824/4885NFKB2 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.